New research published in Neuroscience provides insight into how chronic treatment with escitalopram, a commonly prescribed antidepressant, can reverse anxiety- and despair-like behaviors in adolescent rats that experienced early life stress. The study also suggests that these behavioral improvements may be linked to changes in the brain’s endocannabinoid system, a neuromodulatory network involved in stress regulation and emotional processing.
Escitalopram belongs to a class of antidepressants known as serotonin reuptake inhibitors and is one of the few medications approved for use in adolescents. However, its precise effects on the developing brain remain under investigation. In this new study, researchers examined how the drug influenced behavior and brain chemistry in male rats that had undergone maternal separation—a widely used animal model of early life adversity that mimics aspects of childhood neglect.
The research team focused on the endocannabinoid system, which includes cannabinoid receptors (like CB1), endocannabinoid molecules such as anandamide, and enzymes that regulate their synthesis and breakdown. This system plays a major role in emotional regulation, stress responses, and mood, and is considered a potential target for new treatments for depression and anxiety.
Because depression and anxiety are increasingly common in young people—and current treatments often show limited effectiveness—researchers are eager to identify new biological systems that might help guide more effective therapies. The endocannabinoid system is of particular interest, as it appears to be altered by early life stress and may interact with antidepressant treatment.
In this study, rat pups were separated from their mothers for six hours each day between postnatal day 2 and day 15. This period corresponds to a vulnerable developmental window and has been shown to disrupt the stress response system and emotional regulation later in life. After weaning, the male rats were divided into four groups: some were exposed to maternal separation while others were not, and within both groups, half received daily injections of escitalopram during adolescence (from day 35 to 55), while the others received a saline solution.
To assess behavioral effects, the researchers used three tests during late adolescence: the elevated plus maze (which measures anxiety-related behavior), the open field test (which also assesses anxiety and exploratory behavior), and the forced swim test (a standard method for assessing behavioral despair or depressive-like behavior in animals). After testing, brain tissue was analyzed to measure changes in the expression of genes and proteins involved in the endocannabinoid system.
The behavioral tests showed that rats exposed to early life stress displayed signs of anxiety and despair. In the elevated plus maze, these rats spent less time in the open arms—an indicator of higher anxiety. They also showed shorter grooming times and less exploration in the open field test, and a shorter latency to immobility in the forced swim test, which suggests a higher vulnerability to behavioral despair.
When treated with escitalopram, however, these stress-exposed rats exhibited marked behavioral improvement. They spent more time in the open arms of the maze, more time in the center of the open field, and showed grooming behaviors closer to those of control rats. Escitalopram also increased the time it took for them to become immobile in the forced swim test, suggesting a reduction in despair-like behavior.
To understand the underlying biological mechanisms, the researchers looked at the expression of three key genes in the endocannabinoid system: Cb1r (which encodes the CB1 receptor), Faah (which encodes the enzyme that breaks down anandamide), and Napepld (which encodes the enzyme that produces anandamide). These genes were examined in the amygdala, hippocampus, hypothalamus, and prefrontal cortex—brain regions involved in mood regulation and stress responses.
They found that escitalopram treatment significantly reduced the expression of these genes in the amygdala and hippocampus, particularly in stress-exposed rats. These changes suggest that escitalopram might modulate the activity of the endocannabinoid system in these regions, potentially contributing to its behavioral effects. However, these changes were observed only at the gene expression level. When the researchers examined the corresponding protein levels, they found no statistically significant differences. This mismatch suggests that while the drug affects gene activity, these changes might not always lead to corresponding shifts in protein production—at least not at the time point measured.
The researchers propose that this discrepancy may be explained by other regulatory mechanisms, such as microRNA activity, which can prevent messenger RNA from being translated into protein. Previous studies have shown that early life stress can alter microRNA expression in the brain, and it is possible that escitalopram does not fully reverse these effects.
The study adds to growing evidence that the endocannabinoid system plays a role in how early life stress shapes brain development and emotional behavior. It also raises the possibility that antidepressants like escitalopram may work, in part, by influencing this system—especially during adolescence, a period marked by major changes in brain connectivity and chemistry.
As with all research, however, there are limitations to note. The study measured gene and protein expression at only one time point, 24 hours after the final escitalopram dose. It’s possible that more dynamic or delayed changes occur that were not captured in this analysis. Additionally, the study focused only on male rats, even though sex differences are known to affect both depression risk and the function of the endocannabinoid system.
Future studies will need to examine the time course of these molecular changes, explore protein activity across multiple time points, and compare results between males and females. Understanding how early life stress reshapes the endocannabinoid system—and how drugs like escitalopram might help recalibrate it—could ultimately lead to more effective and personalized treatments for depression and anxiety in young people.
The study, “Escitalopram reverses anxiety-like and despair behavior and affects endocannabinoid-related genes expression in the brain of adolescent male rats subjected to early life stress,” was authored by Jonasz Dragon, Miłosz Gołyszny, Michał Zieliński, Katarzyna Popiołek-Barczyk, Katarzyna Starowicz, and Ewa Obuchowicz.
